CA
ALNY icon

Continuum Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Continuum Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Buy
+38
New +$11.5K ﹤0.01% 1213
2025
Q1 		– Sell
-6
Closed -$1.41K – 1667
2024
Q4 		$1.41K Hold
6
– – ﹤0.01% 1533
2024
Q3 		$1.55K Buy
+6
New +$1.56K ﹤0.01% 1522

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Continuum Advisory's ALNY Position: Q2 2026 in Review

Continuum Advisory opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 38 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #1213 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in ALNY as recently as Q4 2024.

Continuum Advisory first reported a position in ALNY in Q3 2024 and has held it in 3 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Continuum Advisory held 38 shares of Alnylam Pharmaceuticals worth $11.4K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1213 holding.
  • Continuum Advisory first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.